Misconception and challenges of rare disease in research and development of orphan drugs

Rare diseases are those diseases which affect quality of life of both patient and their families. The greatest concern of research and development of pharmaceutical industries is to develop the drug for such disease which is commonly called as orphan drugs. Rare diseases are not at all rarely occurring diseases. In developed countries like Europe and America 25-30 million of patients are suffering from rare diseases and there are about 4000-5000 different types of rare diseases. Several factors have created a challenge and burden on R&D and pharmaceutical industries for upshot of drugs for these diseases. But it’s been a misconception that pharmaceutical industries are neglecting such rare diseases because of lack of understanding the mechanism of these diseases, unavailability of patients for clinical trial purpose, high investment in R&D. But the fact is that investment by industries on R&D for orphan drugs is rising day by day.